Erdinç Nayır, Associate Professor of Internal Medicine and Medical Oncology at VM Medicalpark Mersin Hospital, shared a post on X:
“3 vs 6 months of adjuvant chemotherapy in colorectal cancer (SCOT trial): 5-year OS identical (82.4%).
3 months is non-inferior, with less oxaliplatin-related neuropathy.
Same survival, less toxicity.”
Title: Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
Authors: Timothy Iveson, Mark P. Saunders, Caroline Kelly, Rachel S. Kerr, Jim Cassidy, Niels Henrik Hollander, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, John McQueen, Sarah Pearson, Kathleen A. Boyd, Andrew H. Briggs, Ashita Waterston, Louise Medley, Richard Ellis, Amandeep S. Dhadda, Mark Harrison, Stephen Falk, Charlotte Rees, Rene K. Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Cunningham, Tamas Hickish, Simon Gollins, Harpreet S. Wasan, David Church, Enric Domingo
You can read the full article in JCO ASCO.
More posts on Colorectal Cancer on OncoDaily.